XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Conference. The live presentation will occur at 12:00 p.m. Pacific Time (3:00 p.m. Eastern Time) on Tuesday, September 11, 2012. A replay of the presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com. Please connect to the Website at least 15 minutes prior to the live presentation to ensure adequate time for any software downloads that may be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one month and will be available approximately 24 hours after the live presentation.
About XenoPortXenoPort is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. Horizant ® (gabapentin enacarbil) Extended-Release Tablets is approved in the United States for the treatment of moderate-to-severe primary restless legs syndrome (RLS) in adults and for the management of postherpetic neuralgia in adults. GlaxoSmithKline holds commercialization rights and certain development rights for Horizant in the United States. Regnite ® (gabapentin enacarbil) Extended-Release Tablets is approved and is being marketed for the treatment of RLS in Japan. Astellas Pharma Inc. holds all development and commercialization rights for Regnite in Japan and five other Asian countries. XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. XenoPort’s pipeline of product candidates includes potential treatments for patients with spasticity, Parkinson’s disease and relapsing-remitting multiple sclerosis (RRMS). To learn more about XenoPort, please visit the Website at www.XenoPort.com. XENOPORT and Regnite are registered trademarks of XenoPort, Inc. Horizant is a registered trademark of GlaxoSmithKline. XNPT2G
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV